Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement

JAMA. 2020 Mar 10;323(10):970-975. doi: 10.1001/jama.2020.1123.


Importance: Hepatitis C virus (HCV) is the most common chronic blood-borne pathogen in the US and a leading cause of complications from chronic liver disease. HCV is associated with more deaths than the top 60 other reportable infectious diseases combined, including HIV. Cases of acute HCV infection have increased approximately 3.8-fold over the last decade because of increasing injection drug use and improved surveillance.

Objective: To update its 2013 recommendation, the USPSTF commissioned a review of the evidence on screening for HCV infection in adolescents and adults.

Population: This recommendation applies to all asymptomatic adults aged 18 to 79 years without known liver disease.

Evidence assessment: The USPSTF concludes with moderate certainty that screening for HCV infection in adults aged 18 to 79 years has substantial net benefit.

Recommendation: The USPSTF recommends screening for HCV infection in adults aged 18 to 79 years. (B recommendation).

Publication types

  • Practice Guideline
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antiviral Agents / therapeutic use
  • Asymptomatic Infections
  • Female
  • Hepacivirus*
  • Hepatitis C / diagnosis
  • Hepatitis C / transmission
  • Hepatitis C Antibodies / blood
  • Hepatitis C, Chronic / diagnosis*
  • Hepatitis C, Chronic / drug therapy
  • Humans
  • Male
  • Mass Screening / adverse effects
  • Mass Screening / standards*
  • Middle Aged
  • Young Adult


  • Antiviral Agents
  • Hepatitis C Antibodies